Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Meibomian gland carcinoma
(
MGC
) and basal cell carcinoma (BCC) are common eyelid carcinomas that exhibit highly dissimilar degrees of proliferation and prognoses. We address here the question of the differential mechanisms between these two eyelid cancers that explain their different outcome. A total of 102 confirmed
MGC
and 175 diagnosed BCC cases were analyzed. Twenty confirmed
MGC
and twenty diagnosed BCC cases were collected to determine the telomere length, the presence of senescent cells, and the expression levels of the telomere capping shelterin complex,
P53
, and the E3 ubiquitin ligase Siah1. Decreased protein levels of the shelterin subunits, shortened telomere length, over-expressed Ki-67, and Bcl2 as well as mutations in
P53
were detected both in
MGC
and BCC. It suggests that the decreased protein levels of the shelterin complex and the shortened telomere length contribute to the tumorigenesis of
MGC
and BCC. However, several parameters distinguish
MGC
from BCC samples: (i) the mRNA level of the shelterin subunits decreased in
MGC
but it increased in BCC; (ii)
P53
was more highly mutated in
MGC
; (iii) Siah1 mRNA was over-expressed in BCC; (iv) BCC samples contain a higher level of senescent cells; (v) Ki-67 and Bcl2 expression were lower in BCC. These results support a model where a preserved
P53
checkpoint in BCC leads to cellular senescence and reduced tumor proliferation as compared to
MGC
.
...
PMID:Differential senescence capacities in meibomian gland carcinoma and basal cell carcinoma. 2643